Dalbavancin: A Nationwide Outpatient Experience in Physician Office Infusion Centers (POICs)

Lucinda J. Van Anglen; Robin H. Dretler; Quyen Luu; Ramesh V. Nathan; Barry Statner; Fernando S. Alvarado; Claudia P. Schroeder

doi:10.1093/OFID/OFV133.503

Dalbavancin: A Nationwide Outpatient Experience in Physician Office Infusion Centers (POICs)

Lucinda J. Van Anglen
, Robin H. Dretler
, Quyen Luu
, Ramesh V. Nathan
, Barry Statner
, Fernando S. Alvarado
, Claudia P. Schroeder

1Healix Infusion Therapy, Inc, Sugar Land, Texas
2Infectious Disease Specialists of Atlanta, PC, Decatur, Georgia
3Macon, Georgia
4Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, California
5Infectious Disease Consultants, MD, PA, Altamonte Springs, Florida

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Open Forum Infectious Diseases
Volume	2
DOIs	https://doi.org/10.1093/OFID/OFV133.503
State	Published - Dec 1 2015
Externally published	Yes

Disciplines

Medicine and Health Sciences
Emergency Medicine
Pediatrics

Access to Document

10.1093/OFID/OFV133.503License: Unspecified

Cite this

@article{2c6dff9ec1294da08173319933990739,

title = "Dalbavancin: A Nationwide Outpatient Experience in Physician Office Infusion Centers (POICs)",

author = "\{Van Anglen\}, \{Lucinda J.\} and Dretler, \{Robin H.\} and Quyen Luu and Nathan, \{Ramesh V.\} and Barry Statner and Alvarado, \{Fernando S.\} and Schroeder, \{Claudia P.\}",

note = "Background. Dalbavancin (DAL), a long-acting lipoglycopeptide, was recently approved for the treatment of acute bacterial skin and skin structure infections cau",

year = "2015",

month = dec,

day = "1",

doi = "10.1093/OFID/OFV133.503",

language = "American English",

volume = "2",

journal = "Open Forum Infectious Diseases",

}

TY - JOUR

T1 - Dalbavancin: A Nationwide Outpatient Experience in Physician Office Infusion Centers (POICs)

AU - Van Anglen, Lucinda J.

AU - Dretler, Robin H.

AU - Luu, Quyen

AU - Nathan, Ramesh V.

AU - Statner, Barry

AU - Alvarado, Fernando S.

AU - Schroeder, Claudia P.

N1 - Background. Dalbavancin (DAL), a long-acting lipoglycopeptide, was recently approved for the treatment of acute bacterial skin and skin structure infections cau

PY - 2015/12/1

Y1 - 2015/12/1

UR - https://academic.oup.com/ofid/article/2/suppl_1/786/2635000

U2 - 10.1093/OFID/OFV133.503

DO - 10.1093/OFID/OFV133.503

M3 - Article

VL - 2

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

ER -

Dalbavancin: A Nationwide Outpatient Experience in Physician Office Infusion Centers (POICs)

Disciplines

Access to Document

Other files and links

Cite this